MDS-UPDRS
Cross-source consensus on MDS-UPDRS from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Highlighted claims
- The primary endpoint is the change in MDS-UPDRS Part 3 score from baseline to week 48, measured in the practically defined OFF-medication state. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
- MDS-UPDRS Part 3 assesses motor function on a total score range of 0–132, with higher scores indicating greater severity. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
- The practically defined OFF-medication state is defined as no anti-PD medication taken for more than 12 hours. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study
- Measuring the primary outcome after the 12-week washout is intended to detect a residual change in disease trajectory rather than a symptomatic drug effect. — Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study